TFDs designed envisaging cancer therapy include TFDs targeting NF-KB for inhibition of metastasis, signal transducer and activator of transcription 3, or STAT3, to induce apoptosis and cell cycle arrest in ovarian, glioblastoma, lung and neck cancers (reviewed in [110]). This evidence concerns the gene STAT3 and cancer.